^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GT103

    i
    Other names: GT103
    Associations

    News

    Trials
    Company:
    Duke University, Grid Therap
    Drug class:
    Complement factor H inhibitor
    Associations

    News

    Trials
    7ms
    GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • GT103
    7ms
    HCRN LUN21-497: Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=21, Terminated, Jeffrey Clarke | Trial completion date: Jan 2028 --> Jun 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jun 2025; Study did not meet the criteria for continuation after interim analysis
    Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    Keytruda (pembrolizumab) • GT103
    8ms
    Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (clinicaltrials.gov)
    P1, N=31, Completed, Edward Patz | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    GT103
    9ms
    GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Roswell Park Cancer Institute
    New P2 trial
    |
    Keytruda (pembrolizumab) • GT103
    over1year
    Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Jeffrey Clarke | Suspended --> Active, not recruiting | N=50 --> 21 | Trial completion date: Jan 2030 --> Jan 2028 | Trial primary completion date: Jan 2029 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • GT103
    over1year
    Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Edward Patz | Trial primary completion date: Dec 2024 --> Apr 2024
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    GT103
    over1year
    Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Edward Patz | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    GT103
    almost2years
    Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Suspended, Jeffrey Clarke | Trial primary completion date: Jan 2024 --> Jan 2029
    Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    Keytruda (pembrolizumab) • GT103
    2years
    Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Suspended, Jeffrey Clarke | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    Keytruda (pembrolizumab) • GT103
    2years
    Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Edward Patz | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    GT103
    over2years
    Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) (clinicaltrials.gov)
    P1, N=24, Recruiting, Edward Patz | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    GT103
    over2years
    Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103. (PubMed, Mol Cancer Ther)
    We also demonstrate that GT103 causes B cell activation in vitro and in vivo, and that GT103 antitumor activity in vivo is B cell dependent. The complex mechanism of GT103, a tumor specific antibody that kills tumor cells and stimulates an immune response, supports further development of this human-derived antibody as a novel therapeutic option for patients with lung cancer.
    Journal
    |
    CALR (Calreticulin)
    |
    GT103